Trials
13 active
28 in total · 15 in the EU
What this is
- How it works
- Complement Factor B Inhibitor FDA class
- How it’s given
- “Placebo to iptacopan 200mg b.i.d. (Adults 200mg b.i.d; Adolescents 2x 100mg b.i.d)”In the company’s words, NCT04817618 on ClinicalTrials.gov
- Tested for
- Atypical Hemolytic Uremic Syndrome (2 trials), C3G, Generalized Myasthenia Gravis, Paroxysmal Nocturnal Hemoglobinuria, IC-MPGN, Primary Immunoglobulin A Nephropathy (IgAN), Primary IgA Nephropathy, Paroxysmal Nocturnal Hemoglobinuria (PNH) and 5 more
- Main trialPhase 3
- “The Primary Completion Date and Study Completion Date have been updated to reflect completion of the adolescent cohort, which has been added to the protocol. The study is designed as a multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy.”In the company’s words, NCT04817618 on ClinicalTrials.gov
- Other names
- Iptcaopan · LNP023 · Investigational new drug
Other drugs for Atypical Hemolytic Uremic Syndrome
- CrovalimabRoche · Phase 3
- NM8074NovelMed Therapeutics · Phase 2
- RavulizumabAlexion Pharmaceuticals, Inc. · Marketed (Phase 4 trial)
Coming up12
- 30 DecPhase 2 trial completes · ClinicalTrials.gov
- 29 Jan 2027Phase 3 trial completes · ClinicalTrials.gov
- 30 Apr 2027Phase 3 trial completes · ClinicalTrials.gov
- 18 Oct 2027Phase 3 trial completes · ClinicalTrials.gov
- 27 Nov 2027Phase 2 trial completes · ClinicalTrials.gov
- 21 Jul 2028Phase 3 trial completes · ClinicalTrials.gov
- 27 Oct 2028Phase 3 trial completes · ClinicalTrials.gov
- 28 Jun 2030Phase 3 trial completes · ClinicalTrials.gov
- 4 Dec 2030Phase 3 trial completes · ClinicalTrials.gov
- 14 Oct 2031Phase 3 trial completes · ClinicalTrials.gov
- 16 Jul 2032Phase 3 trial completes · ClinicalTrials.gov
- 30 May 2036Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials28
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 29 Jan 2027 | Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. | |
| Phase 3Active, not recruiting | 30 Apr 2027 | A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | |
| Phase 3Active, not recruiting | 18 Oct 2027 | Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal Hemoglobinuria | |
| Phase 3Recruiting | 21 Jul 2028 | Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS) | |
| Phase 3Recruiting | 27 Oct 2028 | Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN | |
| Phase 3Recruiting | 28 Jun 2030 | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN | |
| Phase 3Recruiting | 4 Dec 2030 | A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy | |
| Phase 3Recruiting | 14 Oct 2031 | Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients | |
| Phase 3Recruiting | 16 Jul 2032 | Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUS | |
| Phase 3Recruiting | 30 May 2036 | Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGN | |
| Phase 2Active, not recruiting | 30 Dec 2026 | Iptacopan in Patients With ANCA Associated Vasculitis | |
| Phase 2Recruiting | 27 Nov 2027 | Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN | |
| Phase 3Completed | 26 Sep 2022 | Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody Treatment | |
| Phase 3Completed | 2 Nov 2022 | Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy | |
| Phase 3Completed | 17 Oct 2024 | Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan. | |
| Phase 3Completed | 19 Sep 2025 | Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients | |
| Phase 3Completed | 11 Apr 2026 | Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor Therapy | |
| Phase 2Completed | 7 Apr 2020 | Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria | |
| Phase 2Completed | 22 Apr 2020 | Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) | |
| Phase 2Completed | 29 Dec 2020 | Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation | |
| Phase 2Completed | 23 Apr 2021 | Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted | |
| Phase 2Completed | 24 May 2022 | Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria | |
| Phase 2Terminated | 20 Jan 2023 | Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous Nephropathy | |
| Phase 2Terminated | 20 Sep 2023 | Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological Disorders | |
| Phase 2Terminated | 19 Mar 2026 | Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | |
| Phase 2Completed | 19 Aug 2026 | A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration | |
| Phase 1Completed | 20 Jun 2022 | Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function. | |
| Phase 3Authorised | not given | An open-label, single-arm, multicenter roll-over extension program (REP) to characterize the long-term safety and tolerability of iptacopan (LNP023) in patients who have completed a clinical trial (parent study) in the iptacopan pediatric program. |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026